PBI2 Real-World Evaluation of Biosimilar Bevacizumab-awwb versus Reference Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in a U.S. Integrated Healthcare Delivery System: 6-Month Interim Analysis
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.073
https://www.valueinhealthjournal.com/article/S1098-3015(21)00290-4/fulltext
Title :
PBI2 Real-World Evaluation of Biosimilar Bevacizumab-awwb versus Reference Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in a U.S. Integrated Healthcare Delivery System: 6-Month Interim Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00290-4&doi=10.1016/j.jval.2021.04.073
First page :
Section Title :
Open access? :
No
Section Order :
10201